Adaptive Biotechnologies Beats Q3 Revenue Estimates With $83.9M, Swings to Profit
ADPT has more than doubled off its 52-week low of $12.
Summary
Adaptive Biotechnologies reported Q3 revenue of $83.9 million, down 11% from a year earlier but well above the $71.6 million IBES estimate, and posted net income of $2.8 million, or $0.02 per share. Adjusted EBITDA came in at $14.3 million versus an expected loss of $495 thousand — a sharp swing past consensus. Operating expenses of $84.4 million still slightly exceeded revenue, leaving operating income at a marginal loss of $457 thousand, so the bottom line leans on non-operating items. The company raised its full-year MRD revenue outlook to $276 million–$286 million. This follows the strong Q2 print on August 5 that beat estimates and came with a raised full-year MRD revenue outlook and plans to separate the Immune Medicine business. The revenue beat and positive adjusted EBITDA support the MRD franchise story; the thin operating margin is the caveat.
At the time of this announcement, ADPT was trading at $28.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $12.00 to $30.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.